Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

sRANKL (total) Human ELISA (Osteoprotegerin Ligand)

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Receptor Activator for Nuclear Factor κ B Ligand, osteoprotegerin ligand, TNF-related activation-induced cytokine
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD193004200R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Cell culture supernatant

Sample Requirements

5 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.5–32 pmol/l

Limit of Detection

0.4 pmol/l

Intra-assay (Within-Run)

n = 8; CV = 9.4%

Inter-assay (Run-to-Run)

n = 4; CV = 12.0%

Spiking Recovery

96,30%

Dilution Linearity

112,30%

Crossreactivity

  • bovine Non-detectable
  • cat Non-detectable
  • dog Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • monkey Non-detectable
  • mouse Non-detectable
  • rabbit Non-detectable
  • rat Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • human Yes
  • pig Yes (recommended dilution 1:12)
Summary

Features

  • It is intended for research use only
  • The total assay time is about 20 hours
  • The kit measures total sRANKL in serum and plasma (EDTA, citrate, heparin)
  • Assay format is 96 wells
  • Quality Controls are native protein based
  • Standard is serum protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Bone and cartilage metabolism, Oncology

Summary

sRANKL, receptor activator of nuclear factor (NF)-κB ligand (also: osteoprotegerin ligand, OPGL), is a part of the TNF superfamily with high similarity to other members of that protein species. (SwissProt Nr. O14788).

Three isoforms are produced by alternate splicing, two type II membrane proteins (ISOFORM 1, 317 AA, and ISOFORM 3, 270 AA), and a secreted molecule (ISOFORM 2, 244 AA). ISOFORM 1 is identical to previously reported RANKL and possesses intracellular, transmembrane, and extracellular domains; ISOFORM 2 does not have the intracellular and transmembrane domains, and ISOFORM 3 does not have the intracellular domain. A soluble form arises by proteolytic processing from membrane isoforms.

Although all forms are bioactive, the membrane-bound proteins seem to be the homeostatic forms, while the production of soluble RANKL signals pathological conditions.

RANKL, RANK, and osteoprotegerin (OPG) have been identified as the key molecular regulation system for bone remodelling. RANKL is the main stimulatory factor for the formation of mature osteoclasts and is essential for their survival. Therefore, an increase in RANKL expression leads to bone resorption and bone loss. RANKL is produced by osteoblastic lineage cells and activated T lymphocytes. It activates its specific receptor RANK, which is located on osteoclasts and dendritic cells. The effects of RANKL are counteracted by OPG, which is secreted by various tissues and acts as an endogenous soluble receptor antagonist.

Imbalances of the RANKL/OPG system have been related to the pathogenesis of Paget’s disease, benign and malignant bone tumors, postmenopausal osteoporosis, rheumatoid arthritis, bone metastases and hypercalcemia. Several studies using animal models have shown that restoring the RANKL/OPG balance (e.g. by administering OPG) reduces the severity of these disorders.

Indication

  • Postmenopausal and senile osteoporosis
  • Diseases with locally increased bone resorption activity
  • Paget´s disease
  • Periodontal disease
  • Cardiovascular disease, arterial calcification
  • Inflammatory diseases
  • Immunological disorders
  • Arthritis
  • Oncology
Product References (47)

References

  • Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y,McClanahan T, Bowman EP. Interleukin-17A upregulates receptor activator ofNF-kappaB on osteoclast precursors. Arthritis Res Ther. 2010;12(1):R29. doi:10.1186/ar2936. Epub 2010 Feb 18. PubMed PMID: 20167120; PubMed Central PMCID:PMC2875663. See more on PubMed
  • Barbagallo I, Vanella A, Peterson SJ, Kim DH, Tibullo D, Giallongo C, Vanella L, Parrinello N, Palumbo GA, Di Raimondo F, Abraham NG, Asprinio D.Overexpression of heme oxygenase-1 increases human osteoblast stem celldifferentiation. J Bone Miner Metab. 2010 May;28(3):276-88. doi:10.1007/s00774-009-0134-y. Epub 2009 Nov 19. PubMed PMID: 19924377; PubMedCentral PMCID: PMC3073406. See more on PubMed
  • Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NM, Hamilton JD.Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate responseto methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016 Oct6;18(1):225. PubMed PMID: 27716324; PubMed Central PMCID: PMC5052933. See more on PubMed
  • Buondonno I, Rovera G, Sassi F, Rigoni MM, Lomater C, Parisi S, Pellerito R,Isaia GC, D'Amelio P. Vitamin D and immunomodulation in early rheumatoidarthritis: A randomized double-blind placebo-controlled study. PLoS One. 2017 Jun5;12(6):e0178463. doi: 10.1371/journal.pone.0178463. eCollection 2017. PubMedPMID: 28582403; PubMed Central PMCID: PMC5459341. See more on PubMed
  • Cao H, Wu Y, Li Q, Wu Y, Zhou Q, Røe OD, Chen Y, Wang R, Wang D. SerumsRANKL/OPG predict recurrence after radiofrequency catheter ablation of loneatrial fibrillation. Int J Cardiol. 2014 Jan 1;170(3):298-302. doi:10.1016/j.ijcard.2013.08.084. Epub 2013 Sep 7. PubMed PMID: 24326209. See more on PubMed
  • Cao H, Zhou Q, Wu Y, Li Q, Røe OD, Chen Y, Wu Z, Wang D. Preoperative serumsoluble receptor activator of nuclear factor-κB ligand and osteoprotegerinpredict postoperative atrial fibrillation in patients undergoing cardiac valvesurgery. Ann Thorac Surg. 2013 Sep;96(3):800-6. doi:10.1016/j.athoracsur.2013.04.042. Epub 2013 Jul 16. PubMed PMID: 23870696. See more on PubMed
  • Cavanagh PR, Rice AJ, Novotny SC, Genc KO, Englehaupt RK, Owings TM, Comstock B, Cardoso T, Ilaslan H, Smith SM, Licata AA. Replacement of daily loadattenuates but does not prevent changes to the musculoskeletal system during bed rest. Bone Rep. 2016 Oct 12;5:299-307. doi: 10.1016/j.bonr.2016.10.001.eCollection 2016 Dec. PubMed PMID: 28580400; PubMed Central PMCID: PMC5440781. See more on PubMed
  • Cucu A, Shreder K, Kraft D, Rühle PF, Klein G, Thiel G, Frey B, Gaipl US,Fournier C. Decrease of Markers Related to Bone Erosion in Serum of Patients withMusculoskeletal Disorders after Serial Low-Dose Radon Spa Therapy. Front Immunol.2017 Jul 25;8:882. doi: 10.3389/fimmu.2017.00882. eCollection 2017. PubMed PMID: 28791026; PubMed Central PMCID: PMC5524779. See more on PubMed
  • D'Amelio P, Cristofaro MA, D'Amico L, Veneziano L, Roato I, Sassi F, BisignanoG, Saracco M, Pellerito R, Patanè S, Ferracini R, Pescarmona GP, Isaia GC.Iloprost modulates the immune response in systemic sclerosis. BMC Immunol. 2010Dec 15;11:62. doi: 10.1186/1471-2172-11-62. PubMed PMID: 21159177; PubMed CentralPMCID: PMC3018379. See more on PubMed
  • Davenport C, Harper E, Rochfort KD, Forde H, Smith D, Cummins PM. RANKLInhibits the Production of Osteoprotegerin from Smooth Muscle Cells under BasalConditions and following Exposure to Cyclic Strain. J Vasc Res.2018;55(2):111-123. doi: 10.1159/000486787. Epub 2018 Apr 10. PubMed PMID:29635231; PubMed Central PMCID: PMC6375687. See more on PubMed
  • Foo JP, Polyzos SA, Anastasilakis AD, Chou S, Mantzoros CS. The effect ofleptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wntinhibitors in young women with hypothalamic amenorrhea. J Clin Endocrinol Metab. 2014 Nov;99(11):E2252-8. doi: 10.1210/jc.2014-2491. Epub 2014 Aug 22. PubMedPMID: 25148234; PubMed Central PMCID: PMC5393498. See more on PubMed
  • Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, Holt SG. FGF-23and osteoprotegerin are independently associated with myocardial damage inchronic kidney disease stages 3 and 4. Another link between chronic kidneydisease-mineral bone disorder and the heart. Nephrol Dial Transplant. 2012Feb;27(2):727-33. doi: 10.1093/ndt/gfr316. Epub 2011 Jul 12. PubMed PMID:21750158. See more on PubMed
  • Friedmann A, Ozmeric N, Bernimoulin JP, Kleber BM, Ayhan E, Aykan T,Gökmenoğlu C. Receptor activator of NF-kappaB ligand (RANKL) and CD 31expressions in chronic periodontitis patients before and after surgery. Cent Eur J Immunol. 2014;39(4):508-17. doi: 10.5114/ceji.2014.47737. Epub 2014 Dec 15.PubMed PMID: 26155171; PubMed Central PMCID: PMC4439964. See more on PubMed
  • Friedrich MJ, Wimmer MD, Schmolders J, Strauss AC, Ploeger MM, Kohlhof H,Wirtz DC, Gravius S, Randau TM. RANK-ligand and osteoprotegerin as biomarkers in the differentiation between periprosthetic joint infection and aseptic prosthesisloosening. World J Orthop. 2017 Apr 18;8(4):342-349. doi: 10.5312/wjo.v8.i4.342. eCollection 2017 Apr 18. PubMed PMID: 28473963; PubMed Central PMCID: PMC5396020. See more on PubMed
  • Garcia Ferrer HR, Azan A, Iraheta I, Von Feldt J, Espinoza LR, Manasson J,Scher JU, Garcia Kutzbach A, Ogdie A. Potential risk factors for reactivearthritis and persistence of symptoms at 2 years: a case-control study withlongitudinal follow-up. Clin Rheumatol. 2018 Feb;37(2):415-422. doi:10.1007/s10067-017-3911-3. Epub 2017 Nov 14. PubMed PMID: 29139030; PubMedCentral PMCID: PMC5776049. See more on PubMed
  • Chandran V, Cook RJ, Edwin J, Shen H, Pellett FJ, Shanmugarajah S, Rosen CF,Gladman DD. Soluble biomarkers differentiate patients with psoriatic arthritisfrom those with psoriasis without arthritis. Rheumatology (Oxford). 2010Jul;49(7):1399-405. doi: 10.1093/rheumatology/keq105. Epub 2010 Apr 25. PubMedPMID: 20421218. See more on PubMed
  • Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT. Soluble receptoractivator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin inankylosing spondylitis: OPG is associated with poor physical mobility andreflects systemic inflammation. Clin Rheumatol. 2010 Oct;29(10):1155-61. doi:10.1007/s10067-010-1543-y. Epub 2010 Aug 6. PubMed PMID: 20690034. See more on PubMed
  • Christoforidis A, Economou M, Farmaki E, Tzimouli V, Gombakis N,Athanassiou-Metaxa M. Increased osteoclastic activity as shown by increasedsRANK-L/OPG ratio in boys with hemophilia. Ann Hematol. 2010 Aug;89(8):837-8.doi: 10.1007/s00277-009-0894-4. Epub 2010 Jan 19. PubMed PMID: 20084381. See more on PubMed
  • Christoforidis A, Economou M, Papadopoulou E, Kazantzidou E, Farmaki E,Tzimouli V, Tsatra I, Gompakis N, Athanassiou-Metaxa M. Comparative study of dualenergy X-ray absorptiometry and quantitative ultrasonography with the use ofbiochemical markers of bone turnover in boys with haemophilia. Haemophilia. 2011 Jan;17(1):e217-22. doi: 10.1111/j.1365-2516.2010.02385.x. Epub 2010 Sep 2. PubMedPMID: 20825502. See more on PubMed
  • Johansson L, Ärlestig L, Kokkonen H, Brink M, Rantapää-Dahlqvist S. Anincreased concentration of receptor activator of nuclear factor kappa-B ligandpre-dates the onset of rheumatoid arthritis. Rheumatology (Oxford). 2017 Dec1;56(12):2190-2196. doi: 10.1093/rheumatology/kex339. PubMed PMID: 29029341. See more on PubMed
  • Kirschneck C, Küchler EC, Wolf M, Spanier G, Proff P, Schröder A. Effects ofthe Highly COX-2-Selective Analgesic NSAID Etoricoxib on Human PeriodontalLigament Fibroblasts during Compressive Orthodontic Mechanical Strain. Mediators Inflamm. 2019 Mar 10;2019:2514956. doi: 10.1155/2019/2514956. eCollection 2019.PubMed PMID: 30983880; PubMed Central PMCID: PMC6431464. See more on PubMed
  • Konca Degertekin C, Turhan Iyidir O, Aktas Yılmaz B, Elbeg S, Pasaoglu OT,Pasaoglu H, Cakır N, Arslan M. RANKL/Osteoprotegerin System and Bone Turnover in Hashimoto Thyroiditis. Calcif Tissue Int. 2016 Oct;99(4):365-72. doi:10.1007/s00223-016-0163-1. Epub 2016 Jun 22. PubMed PMID: 27328677. See more on PubMed
  • Kos O, Hughson RL, Hart DA, Clément G, Frings-Meuthen P, Linnarsson D, PaloskiWH, Rittweger J, Wuyts F, Zange J, Gorczynski RM. Elevated serum soluble CD200and CD200R as surrogate markers of bone loss under bed rest conditions. Bone.2014 Mar;60:33-40. doi: 10.1016/j.bone.2013.12.004. Epub 2013 Dec 9. PubMed PMID:24333170. See more on PubMed
  • Krela-Kaźmierczak I, Kaczmarek-Ryś M, Szymczak A, Michalak M,Skrzypczak-Zielińska M, Drwęska-Matelska N, Marcinkowska M, Eder P,Łykowska-Szuber L, Wysocka E, Linke K, Słomski R. Bone Metabolism and thec.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene inPatients with Inflammatory Bowel Disease. Calcif Tissue Int. 2016Dec;99(6):616-624. Epub 2016 Sep 17. PubMed PMID: 27639566; PubMed Central PMCID:PMC5097783. See more on PubMed
  • Kuo PL, Liao SH, Hung JY, Huang MS, Hsu YL. MicroRNA-33a functions as a bonemetastasis suppressor in lung cancer by targeting parathyroid hormone relatedprotein. Biochim Biophys Acta. 2013 Jun;1830(6):3756-66. doi:10.1016/j.bbagen.2013.02.022. Epub 2013 Mar 1. PubMed PMID: 23458685. See more on PubMed
  • Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA,Dimopoulou MN, Angelopoulou MK, Pangalis GA. Serum syndecan-1, basic fibroblastgrowth factor and osteoprotegerin in myeloma patients at diagnosis and during thecourse of the disease. Eur J Haematol. 2004 Apr;72(4):252-8. PubMed PMID:15089762. See more on PubMed
  • Lee SM, Lee HW, Son YK, Kim SE, An WS. Abdominal aortic calcification scoreamong several vascular calcification scores of plain radiograph is the mostreliable predictor of severe coronary artery calcification in dialysis patients. Ren Fail. 2017 Nov;39(1):729-735. doi: 10.1080/0886022X.2017.1398666. PubMedPMID: 29157086; PubMed Central PMCID: PMC6446146. See more on PubMed
  • Lipe B, Kambhampati S, Veldhuizen PV, Yacoub A, Aljitawi O, Mikhael J.Correlation between markers of bone metabolism and vitamin D levels in patientswith monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer J.2017 Dec 14;7(12):646. doi: 10.1038/s41408-017-0015-x. PubMed PMID: 29238066;PubMed Central PMCID: PMC5802504. See more on PubMed
  • Luque RM, López-Sánchez LM, Villa-Osaba A, Luque IM, Santos-Romero AL,Yubero-Serrano EM, Cara-García M, Álvarez-Benito M, López-Mirand A J, Gahete MD, Castaño JP. Breast cancer is associated to impaired glucose/insulin homeostasisin premenopausal obese/overweight patients. Oncotarget. 2017 Aug23;8(46):81462-81474. doi: 10.18632/oncotarget.20399. eCollection 2017 Oct 6.PubMed PMID: 29113405; PubMed Central PMCID: PMC5655300. See more on PubMed
  • Mazur P, Wypasek E, Gawęda B, Sobczyk D, Kapusta P, Natorska J, Malinowski KP,Tarasiuk J, Bochenek M, Wroński S, Chmielewska K, Kapelak B, Undas A. StenoticBicuspid and Tricuspid Aortic Valves - Micro-Computed Tomography and BiologicalIndices of Calcification. Circ J. 2017 Jun 23;81(7):1043-1050. doi:10.1253/circj.CJ-16-1166. Epub 2017 Mar 24. PubMed PMID: 28344201. See more on PubMed
  • Meng YH, Li H, Chen X, Liu LB, Shao J, Chang KK, Du MR, Jin LP, Li MQ, Li DJ. RANKL promotes the growth of decidual stromal cells in an autocrine manner viaCCL2/CCR2 interaction in human early pregnancy. Placenta. 2013 Aug;34(8):663-71. doi: 10.1016/j.placenta.2013.04.020. Epub 2013 May 19. PubMed PMID: 23697850. See more on PubMed
  • Mohamed JA, DuPont HL, Jiang ZD, Flores J, Carlin LG, Belkind-Gerson J,Martinez-Sandoval FG, Guo D, White AC Jr, Okhuysen PC. A single-nucleotidepolymorphism in the gene encoding osteoprotegerin, an anti-inflammatory proteinproduced in response to infection with diarrheagenic Escherichia coli, isassociated with an increased risk of nonsecretory bacterial diarrhea in NorthAmerican travelers to Mexico. J Infect Dis. 2009 Feb 15;199(4):477-85. doi:10.1086/596319. PubMed PMID: 19128145; PubMed Central PMCID: PMC2742228. See more on PubMed
  • Morena M, Bosc JY, Jaussent I, Dupuy AM, Terrier N, Leray-Moragues H, Flavier JL, Maurice F, Delcourt C, Cristol JP, Canaud B. The role of mineral metabolismand inflammation on dialysis vascular access failure. J Vasc Access. 2006Apr-Jun;7(2):77-82. PubMed PMID: 16868901. See more on PubMed
  • Motovska Z, Vichova T, Tousek P, Dusek L, Widimsky P. Circulatingosteoprotegerin and Dickkopf-1 changed significantly after surgical aortic valve replacement but remained without any significant differences after transcatheter aortic valve implantation. Int J Cardiol. 2012 Jul 12;158(2):300-1. doi:10.1016/j.ijcard.2012.04.115. Epub 2012 May 14. PubMed PMID: 22592030. See more on PubMed
  • Nagy E, Eriksson P, Yousry M, Caidahl K, Ingelsson E, Hansson GK,Franco-Cereceda A, Bäck M. Valvular osteoclasts in calcification and aortic valvestenosis severity. Int J Cardiol. 2013 Oct 3;168(3):2264-71. doi:10.1016/j.ijcard.2013.01.207. Epub 2013 Feb 27. PubMed PMID: 23452891. See more on PubMed
  • Nezami N, Safa J, Eftekhar-Sadat AT, Salari B, Ghorashi S, Sakhaee K,Khosraviani K. Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy. Clin Biochem. 2010 Nov;43(16-17):1294-9. doi:10.1016/j.clinbiochem.2010.08.012. Epub 2010 Aug 19. PubMed PMID: 20727867. See more on PubMed
  • Onami I, Ayabe M, Murao N, Ishigai M. A versatile method for protein-basedantigen bioanalysis in non-clinical pharmacokinetics studies of a humanmonoclonal antibody drug by an immunoaffinity liquid chromatography-tandem massspectrometry. J Chromatogr A. 2014 Mar 21;1334:64-71. doi:10.1016/j.chroma.2014.01.082. Epub 2014 Feb 7. PubMed PMID: 24572547. See more on PubMed
  • Ozçaka O, Nalbantsoy A, Köse T, Buduneli N. Plasma osteoprotegerin levels are decreased in smoker chronic periodontitis patients. Aust Dent J. 2010Dec;55(4):405-10. doi: 10.1111/j.1834-7819.2010.01261.x. PubMed PMID: 21133939. See more on PubMed
  • Ozkaya O, Buyan N, Bideci A, Gonen S, Ortac E, Fidan K, Cinaz P, Söylemezoğlu O. Osteoprotegerin and RANKL serum levels and their relationship with serumghrelin in children with chronic renal failure and on dialysis. Nephron ClinPract. 2007;105(4):c153-8. Epub 2007 Jan 25. PubMed PMID: 17259742. See more on PubMed
  • Öztürk VÖ, Emingil G, Bostanci N, Belibasakis GN. Impact of implant-abutmentconnection on osteoimmunological and microbiological parameters in shortimplants: a randomized controlled clinical trial. Clin Oral Implants Res. 2017Sep;28(9):e111-e120. doi: 10.1111/clr.12937. Epub 2016 Jul 29. PubMed PMID:27469171. See more on PubMed
  • Ren W, Blasier R, Peng X, Shi T, Wooley PH, Markel D. Effect of oralerythromycin therapy in patients with aseptic loosening of joint prostheses.Bone. 2009 Apr;44(4):671-7. doi: 10.1016/j.bone.2008.12.015. Epub 2008 Dec 29.PubMed PMID: 19154802. See more on PubMed
  • Rydzon B, Monson RS, Oberholzer J, Varady KA, Bellin MD, Danielson KK. Longterm (4 years) improved insulin sensitivity following islet cell transplant intype 1 diabetes. Diabetes Metab Res Rev. 2018 Mar;34(3). doi: 10.1002/dmrr.2972. Epub 2018 Jan 11. PubMed PMID: 29230944; PubMed Central PMCID: PMC5873303. See more on PubMed
  • Sassi F, Buondonno I, Luppi C, Spertino E, Stratta E, Di Stefano M, Ravazzoli M, Isaia G, Trento M, Passera P, Porta M, Isaia GC, D'Amelio P. Type 2 diabetesaffects bone cells precursors and bone turnover. BMC Endocr Disord. 2018 Aug8;18(1):55. doi: 10.1186/s12902-018-0283-x. PubMed PMID: 30089481; PubMed CentralPMCID: PMC6083573. See more on PubMed
  • Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, Colak A, Yalcin H,Gunay N, Akkoc N. Biomarkers and cytokines of bone turnover: extensive evaluationin a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord.2012 Oct 2;13:191. doi: 10.1186/1471-2474-13-191. PubMed PMID: 23025387; PubMedCentral PMCID: PMC3492209. See more on PubMed
  • Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A,Conticello C, Palumbo GA, Di Raimondo F. Effects of imatinib mesylate inosteoblastogenesis. Exp Hematol. 2009 Apr;37(4):461-8. doi:10.1016/j.exphem.2008.12.008. PubMed PMID: 19302920. See more on PubMed
  • Yao S, Zhang Y, Tang L, Roh JM, Laurent CA, Hong CC, Hahn T, Lo JC, Ambrosone CB, Kushi LH, Kwan ML. Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis. Breast Cancer Res Treat. 2017Feb;161(3):501-513. doi: 10.1007/s10549-016-4068-5. Epub 2016 Dec 3. PubMed PMID:27915435; PubMed Central PMCID: PMC5243170. See more on PubMed
  • Zdzisińska B, Bojarska-Junak A, Walter-Croneck A, Kandefer-Szerszeń M.Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerinproduction influence the apoptosis of multiple myeloma patients' bone marrowstromal cells co-cultured with myeloma cells. Arch Immunol Ther Exp (Warsz). 2010Apr;58(2):153-63. doi: 10.1007/s00005-010-0070-5. Epub 2010 Feb 16. PubMed PMID: 20157786. See more on PubMed
Summary References (14)

References to RANKL

  • Hofbauer L.C et al. Effect of oral contraceptives on circulatingosteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol (2004) 60: 214–219
  • Ito S. et al. Crystal structure of the extracellular domain of mouse ligand at2.2-A resolution. J Biol Chem (2002) 22: 6631–6636.
  • Lam J. et al. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptorligand specifity. J Clin Invest (2001) 108: 971–979.
  • Lacey D.L, et al., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998), 93:165–176.
  • Kong Y.Y. et al., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999), 397: 315–323.
  • Hsu H. et al., Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci (1999), 96:3540–3545.
  • Josien R. et al, TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med (2000), 191: 495–502.
  • Fuller K. et al., TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med (1998), 188: 997–1001.
  • Nakashima T. et. al., Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun (2000), 275(3):768–775.
  • Kong Y.Y. et al., Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999), 402: 304–309.
  • Hofbauer L.C. & A.E. Heufelder, Role of receptor activator of nuclear factor-KB ligand and osteoprotegerin in bone cell biology. J Mol Med (2001), 79: 243–253.
  • Hofbauer L.C. & A.E. Heufelder, The Role of Osteoprotegerin and Receptor Activator of Nuclear Factor κB Ligand in the Pathogenesis and Treatment of Rheumatoid Arthritis. Arthritis & Rheumatism (2001), 44:253–259.
  • Hofbauer LC, et al. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab (2000), 85: 2355–2363.
  • Teitelbaum S.L., Bone resorption by osteoclasts. Science (2000), 289: 1504–1508.
Related Products Docs